EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Triple-regulated conditionally replicating adenovirus for effective and safer treatment of peritoneal carcinomatosis

Junichi Kamizono, Yuya Nishikawaji, Satoshi Nagano, Minako Ikeda, Yoshiharu Horikawa, Taro Kamisasanuki, Kaoru Mitsui, Eriko Matsuda, Ken-Ichiro Kosai

Biochemical and Biophysical Research Communications · 2024

DOI: 10.1016/j.bbrc.2024.150894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Junichi Kamizono und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagosh…. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Virus Replication, Adenoviridae, Oncolytic Virotherapy. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is no effective therapy for peritoneal carcinomatosis derived from gastric cancer. An ideal conditionally replicating adenovirus (CRA) that selectively replicates in and kills cancer cells has not been developed for gastric cancer-derived peritoneal carcinomatosis. Using our platform technology of CRA regulated and treating tumors with multiple factors (m-CRA), we generated two types of survivin-responsive m-CRAs, Surv.m-CRA-CMVp and Surv.m-CRA-CEAp, consisting of E1A downstream of the survivin promoter, and the mutated E1B gene downstream of the human cytomegalovirus immediate early gene enhancer/promoter and carcinoembryonic antigen promoter, respectively. Survivin mRNA was expressed at high and undetectable levels in two gastric cancer cells and eleven normal cells, respectively. Carcinoembryonic antigen was expressed at high and very low levels in MKN-45 gastric cancer and normal PrEC cells, respectively, and was not detected in other cell types. While both Surv.m-CRA-CEAp and Surv.m-CRA-CMVp exhibited potent cytotoxic effects on MKN-45 cells in vitro, Surv.m-CRA-CEAp significantly reduced cytotoxicity to normal cells compared to Surv.m-CRA-CMVp. Control mice that received an intraperitoneal injection of MKN-45 cells gradually lost body weight and died of peritoneal carcinomatosis within 98 days. In contrast, all mice receiving Surv.m-CRA-CEAp or Surv.m-CRA-CMVp-infected MKN-45 cells increased their body weight and survived 120 days. In conclusion, the triple-regulated Surv.m-CRA-CEAp enhances cancer specificity (i.e., safety) without reducing the potent therapeutic effect for carcinoembryonic antigen-positive gastric cancer-derived peritoneal carcinomatosis. The modified E1B promoter strategy of CRA facilitates the development of novel CRAs for the effective and safe treatment of a variety of refractory cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal NeoplasmsVirus ReplicationAdenoviridaeOncolytic VirotherapySurvivinStomach NeoplasmsAnimalsHumansCell Line, TumorMiceMice, NudePromoter Regions, GeneticInhibitor of Apoptosis ProteinsMice, Inbred BALB CCarcinoembryonic AntigenXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Carcinoembryonic antigen (CEA)Conditionally replicating adenovirus regulated and treating tumors with multipl…Gastric cancerGene therapyOncolytic virusSurvivin

Substanzen

SurvivinInhibitor of Apoptosis ProteinsCarcinoembryonic AntigenBIRC5 protein, human

Autor:innen und Institutionen

  • Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; Department of Orthopaedic Surgery, Kagoshima Univ…
  • Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.
  • Department of Orthopaedic Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; Center for Innovative Therapy Research and Application, Kagoshima Un…
  • Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; Center for Innovative Therapy Research and Applic…

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Kamizono, J., Nishikawaji, Y., Nagano, S., Ikeda, M., Horikawa, Y., Kamisasanuki, T., Mitsui, K., Matsuda, E., & Kosai, K. I. (2024). Triple-regulated conditionally replicating adenovirus for effective and safer treatment of peritoneal carcinomatosis. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150894

Vancouver

Kamizono J, Nishikawaji Y, Nagano S, Ikeda M, Horikawa Y, Kamisasanuki T, et al. Triple-regulated conditionally replicating adenovirus for effective and safer treatment of peritoneal carcinomatosis. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150894

BibTeX
@article{Kamizono2024,
  author = {Kamizono, Junichi and Nishikawaji, Yuya and Nagano, Satoshi and Ikeda, Minako and Horikawa, Yoshiharu and Kamisasanuki, Taro and Mitsui, Kaoru and Matsuda, Eriko and Kosai, Ken-Ichiro},
  title = {Triple-regulated conditionally replicating adenovirus for effective and safer treatment of peritoneal carcinomatosis},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2024},
  doi = {10.1016/j.bbrc.2024.150894}
}
Kostenlos starten →